Albumin-based delivery systems: Recent advances, challenges, and opportunities
Journal of Controlled Release · 2025-04 · 380 · 375-395
DOI: 10.1016/j.jconrel.2025.01.035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2025-04. Verfasst von Gillian Murphy und 5 weiteren Autor:innen. Beteiligte Einrichtung: CÚRAM, the Research Ireland Centre for Medical Devices, University of Galway, Ireland. Electronic address: g.murphy9@universityofgalway.ie. Hauptthemen laut MEDLINE: Drug Delivery Systems, Albumins, Drug Carriers. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Regional Development Fund, Viatris Inc, Science Foundation Ireland.
Abstract (Originalsprache)
Albumin and albumin-based biomaterials have been explored for various applications, including therapeutic delivery, as therapeutic agents, as components of tissue adhesives, and in tissue engineering applications. Albumin has been approved as a nanoparticle containing paclitaxel (Abraxane®), as an albumin-binding peptide (Victoza®), and as a glutaraldehyde-crosslinked tissue adhesive (BioGlue®). Albumin is also approved as a supportive therapy for various conditions, including hypoalbuminemia, sepsis, and acute respiratory distress syndrome (ARDS). However, no other new albumin-based systems in a hydrogel format have been used in the clinic. A review of publicly available clinical trials indicates that no new albumin drug delivery formats are currently in the clinical development pipeline. Although albumin has shown promise as a carrier of therapeutics for various diseases, including diabetes, cancers, and infectious diseases, its potential for treating blood-borne diseases such as HIV and leukemia has not been translated. This review offers a perspective on the use of albumin-based drug delivery systems for a broader range of disease applications, considering the protein properties and a review of the currently approved albumin-based technologies. This review supports ongoing efforts to advance biomedical research and clinical interventions through albumin-based delivery systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CÚRAM, the Research Ireland Centre for Medical Devices, University of Galway, Ireland. Electronic address: g.murphy9@universityofgalway.ie.
- CÚRAM, the Research Ireland Centre for Medical Devices, University of Galway, Ireland; School of Veterinary Medicine and Conway Institute, University College Dublin, Ireland.
- CÚRAM, the Research Ireland Centre for Medical Devices, University of Galway, Ireland; School of Biological and Chemical Science, University of Galway, Ireland.
- Diabetes, Endocrinology and General Internal Medicine, Galway University Hospital, Galway, Ireland.
- Department of Product Development, Viatris, Galway, Ireland.
- CÚRAM, the Research Ireland Centre for Medical Devices, University of Galway, Ireland. Electronic address: abhay.pandit@universityofgalway.ie.
Förderung
- European Regional Development Fund
- Viatris Inc
- Science Foundation Ireland
Zitieren
APA
Murphy, G., Brayden, D. J., Cheung, D. L., Liew, A., Fitzgerald, M., & Pandit, A. (2025). Albumin-based delivery systems: Recent advances, challenges, and opportunities. Journal of Controlled Release, 380, 375-395. https://doi.org/10.1016/j.jconrel.2025.01.035
Vancouver
Murphy G, Brayden DJ, Cheung DL, Liew A, Fitzgerald M, Pandit A. Albumin-based delivery systems: Recent advances, challenges, and opportunities. Journal of Controlled Release. 2025;380:375-395. doi:10.1016/j.jconrel.2025.01.035
BibTeX
@article{Murphy2025,
author = {Murphy, Gillian and Brayden, David J and Cheung, David L and Liew, Aaron and Fitzgerald, Michael and Pandit, Abhay},
title = {Albumin-based delivery systems: Recent advances, challenges, and opportunities},
journal = {Journal of Controlled Release},
year = {2025},
volume = {380},
pages = {375--395},
doi = {10.1016/j.jconrel.2025.01.035}
}
EUVIMED